Skip to main navigation PATIENT PHARMA DIAGNOSTICS COVID-19 SCIENCE CLINICAL STUDIES Investors Home Investor Relations Investors Corporate Profile CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, CENTOGENE is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. CENTOGENE provides the full spectrum of modern methods and technology for human genetics analysis. We are active in research and are constantly developing new and innovative products for human genetics. We are focused on helping to end the diagnostic odyssey of our patients by offering the broadest genetic diagnostic portfolio, and on using our global knowledge of rare hereditary diseases to provide solutions for our pharmaceutical partners that accelerate the development of orphan drugs. We are committed to ‘un-rare’ rare diseases by using our worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3800 diseases and developing innovative biomarkers. Based on this knowledge we are bringing rationality to treatment decisions and, thereby, accelerate the development of new orphan drugs. Change Volume 52 Week High 52 Week Low Nov 24, 2021 12:36 AM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. News Releases Nov 18, 2021 CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021 CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial results for Read More Nov 04, 2021 CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases Providing Global Clinical Trial Support for Thalassemia and Sickle Cell Disease Will Deepen Understanding of Disease Characterization in the Search for a Treatment CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. Read More Oct 28, 2021 CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN) Study will enroll and genetically test over 3,000 FTD patients at multiple sites in seven countries There are currently no Read More VIEW ALL RELEASES Events Nov 24, 2021 at 8:00 AM EST 2021 Q3 Earnings Conference Call Add to Outlook Add to Google Calendar Webcast Nov 8 - Nov 11, 2021 30th Annual Credit Suisse Healthcare Conference Sep 14, 2021 Baird Global Healthcare Conference VIEW ALL EVENTS Featured Publications Q2 2021 Earnings Presentation Investor Event Presentation June 2021 Q4 & Full Year 2020 Earnings Presentation Centogene General Corporate Presentation 2021 Q3 2020 Earnings Presentation H1 2020 Earnings Presentation Q1 2020 Earnings Presentation FY2019 Earnings Presentation 2019 Q3 Earnings Presentation Genetic, clinical and biochemical characterization of a large cohort of patients with hyaline fibromatosis syndrome Pagination Current page 1 Page 2 Next page next › Last page last » Toolkit Print Page Email Alerts Contact IR Pharma Diagnostics Company Newsletter SUBSCRIBE NOW Follow Us © 2021 CENTOGENE N.V. Imprint Data Protection HIPAA Privacy Terms of Use Terms and Conditions Whistleblower Hotline